MDACC Study No:2006-1068 ( NCT No: NCT00491855)
Title:Phase I trial of intraperitoneal oxaliplatin and paclitaxel plus intravenous paclitaxel and bevacizumab in the treatment of advanced peritoneal carcinomatosis
Principal Investigator:Apostolia M. Tsimberidou
Treatment Agent:Bevacizumab; Oxaliplatin; Paclitaxel
Study Status:Terminated
Study Description:The goal of this clinical research is to learn acceptable dosages of
paclitaxel, oxaliplatin, and Avastin (bevacizumab) that can be given in
combination to patients with advanced peritoneal carcinomatosis. The safety of
this drug combination will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Advanced Cancers; Solid Tumors
Phase of Study:Phase I
Treatment Agents:Bevacizumab
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:During each cycle, the patient will be admitted for 3 days (d1 to d3) to have
intravenous bevacizumab, continuous intravenous infusion of paclitaxel and
intraperitoneal oxaliplatin; and then for 2 days (d8 to d9) to have
intraperitoneal paclitaxel.
Supported By:N/A
Return Visit:The patient will have office visit once every 21 days or sooner as needed, and
be admitted for treatment as mentioned above.
Home Care:The initial or loading doses of bevacizumab and paclitaxel will be given in the
clinic. Subsequent doses may be given at home.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Apostolia M. Tsimberidou
Dept:Investigational Cancer Therapeutics
For Clinical Trial Enrollment:713-792-4259
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults